165 related articles for article (PubMed ID: 32650189)
1. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract][Full Text] [Related]
2. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
3. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
4. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract][Full Text] [Related]
5. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
7. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
8. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
9. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
[TBL] [Abstract][Full Text] [Related]
10. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
11. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
12. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
14. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
15. Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study.
Yoon EL; Yuk JS
J Clin Endocrinol Metab; 2021 May; 106(6):1773-1782. PubMed ID: 33567071
[TBL] [Abstract][Full Text] [Related]
16. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
17. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
19. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Gatti M; Poluzzi E; De Ponti F; Raschi E
Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
